BlueRock Therapeutics names new chief legal and administrative officer
27 November 2018 -

BlueRock Therapeutics LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, announced yesterday that it has named Min Wang, JD, PhD, as its chief legal and administrative officer.

In her new role, Dr Wang will join the company's executive team, and hold broad management responsibility for all of the business's legal aspects, including intellectual property, contracts, financial and corporate governance and risk management, as well as management of administrative functions at the company.

Dr Wang has more than 20 years of senior leadership and legal experience in the biotechnology industry. She was most recently senior vice president, general counsel and corporate secretary at Agios Pharmaceuticals Inc, from its inception until the IPO process. Prior to Agios, Dr Wang served as senior patent counsel at Genentech and Merck, where she managed a wide range of therapeutic portfolios in oncology, immunology and antifungal products and negotiated research partnerships. Prior to Merck, Dr Wang was employed in the law firm of Fish & Neave in their Intellectual Property group.